Abbott's Exact Sciences buy, Blackstone and TPG's Hologic acquisition, and Water's BD transaction could herald a busy 2026 ...
The new financial agreements include $5 million of new term-loan proceeds to strengthen liquidity and funding for continued investment in product development.
The US Food and Drug Administration cleared a number of molecular tests and immunoassays, as well as a clinical chemistry and a cellular deformation test.
The court invalidated a patent owned by South Korean firm GXD-Bio and rejected the firm's claims that Myriad's EndoPredict breast cancer test infringed on its intellectual property.
The digital revolution is now more quickly transforming pathology lab workflows, pointing towards accelerating adoption in the coming years.
The false negative rates do not appear out of line with the test's sensitivity figures, but issues have been raised with its workflow and the firm's marketing strategy.
The deal covers Myriad tests used for hereditary cancer risk assessment, as well as for ovarian and prostate cancer treatment.
Over the year multiple clinical trial readouts validated the use of MRD for multiple indications, while companies in the space began to consolidate.
NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback